E. Steliarova-foucher, C. Stiller, P. Kaatsch, F. Berrino, J. W. Coebergh et al., Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project): an epidemiological study, Lancet, vol.364, issue.9451, pp.2097-2105, 2004.

E. Pasquier, M. Kavallaris, and N. André, Metronomic chemotherapy: new rationale for new directions, Nature Reviews Clinical Oncology, vol.7, issue.8, pp.455-65, 2010.

H. A. Perroud, C. M. Alasino, M. J. Rico, L. E. Mainetti, F. Queralt et al., Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response, Cancer Chemother Pharmacol, vol.77, issue.2, pp.365-74, 2016.

D. A. Salem, N. M. Gado, N. N. Abdelaziz, A. E. Essa, Z. M. Abdelhafeez et al., Phase II trial of metronomic chemotherapy as salvage therapy for patients with metastatic breast cancer

, J Egypt Natl Canc Inst, vol.20, issue.2, pp.134-174, 2008.

T. Nelius, K. Rinard, and S. Filleur, Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature, Cancer Treat Rev, vol.37, issue.6, pp.444-55, 2011.

D. Zapletalova, N. André, L. Deak, M. Kyr, V. Bajciova et al., Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience, Oncology, 2012.

M. W. Kieran, C. D. Turner, J. B. Rubin, S. N. Chi, M. A. Zimmerman et al., A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer, J Pediatr Hematol Oncol, vol.27, issue.11, pp.573-81, 2005.

N. J. Robison, F. Campigotto, S. N. Chi, P. E. Manley, C. D. Turner et al., A phase II trial of multi-agent oral anti-angiogenic (metronomic) regimen in children with recurrent or progressive cancer, Pediatr Blood Cancer, vol.61, issue.4, pp.636-678, 2014.

N. André, A. Rome, C. Coze, L. Padovani, E. Pasquier et al.,

, Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study, Clin Ther, 2008.

M. Colleoni, A. Rocca, M. T. Sandri, L. Zorzino, G. Masci et al., Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels, Ann Oncol, vol.13, issue.1, pp.73-80, 2002.

E. Pasquier, N. André, and D. Braguer, Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment, Curr Cancer Drug Targets, 2007.

H. Tanaka, H. Matsushima, A. Nishibu, B. E. Clausen, and A. Takashima, Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation, Cancer Res, vol.69, issue.17, pp.6987-94, 2009.

R. S. Kerbel and B. A. Kamen, The anti-angiogenic basis of metronomic chemotherapy, Nat Rev Cancer, vol.4, issue.6, pp.23-36, 2004.

F. Ponthan, M. Wickström, H. Gleissman, O. M. Fuskevåg, L. Segerström et al., Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo, Clin Cancer Res, vol.13, issue.3, pp.1036-1080, 2007.

M. Porkholm, S. Toiviainen-salo, R. Seuri, T. Lönnqvist, K. Vepsäläinen et al., Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential, Acta Paediatr, vol.105, issue.8, pp.946-51, 2016.

N. Andre and E. Pasquier, Metronomics during palliative care in paediatric oncology? For sure! But handle me with care, Acta Paediatr, vol.105, issue.8, pp.874-879, 2016.

J. Sterba, D. Valik, P. Mudry, T. Kepak, Z. Pavelka et al., Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study, Onkologie, vol.29, pp.308-313, 2006.

J. Choi, N. Kamani, L. Fond, D. Packer, R. J. Santi et al., Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors, Pediatr Blood Cancer, vol.50, issue.5, pp.970-975, 2008.

A. M. Ali and M. I. El-sayed, Metronomic chemotherapy and radiotherapy as salvage treatment in refractory or relapsed pediatric solid tumours, Curr Oncol, vol.23, issue.3, pp.253-262, 2016.

A. Peyrl, M. Chocholous, M. W. Kieran, A. A. Azizi, C. Prucker et al., Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors, Pediatr Blood Cancer, vol.59, issue.3, pp.511-518, 2012.

A. Verschuur, M. A. Heng-maillard, D. , P. Truillet, R. Jouve et al., Paediatric metronomic four-drug metronomic regimen has anti-tumour activity in pediatric low-grade glioma; the results of a phase II clinical trial, Front. Pharmacol, vol.9, p.950

, World Health Organization (1979) WHO Handbook for reporting results of cancer treatment, vol.48

A. B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler, Reporting results of cancer treatment, Cancer, vol.47, issue.1, pp.207-214, 1981.

S. L. Cohn, The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report, J Clin Oncol, vol.27, issue.2, pp.289-297, 2009.

N. André, M. Carré, and E. Pasquier, Metronomics: towards personalized chemotherapy?, Nat Rev Clin Oncol, vol.11, issue.7, pp.413-444, 2014.

R. Pramanik, S. Agarwala, Y. K. Gupta, S. Thulkar, S. Vishnubhatla et al., Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial, JAMA Oncol, vol.3, issue.9, pp.1222-1227, 2017.

A. A. Senerchia, C. R. Macedo, S. Ferman, M. Scopinaro, W. Cacciavillano et al.,

D. Barreto, J. H. El-jaick, T. Aguiar, S. Brunetto, A. Greggiani et al., Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment, Cancer, vol.123, issue.6, pp.1003-1010, 2017.

E. Pasquier, N. André, J. Street, A. Chougule, B. Rekhi et al., Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study, EBioMedicine, vol.6, p.36, 2016.

R. Bagatell, W. B. London, L. M. Wagner, S. D. Voss, C. F. Stewart et al., Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study, J Clin Oncol, vol.29, issue.2, pp.208-221, 2011.

A. Di-giannatale, N. Dias-gastellier, A. Devos, M. Hugh, K. Boubaker et al., Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study, Eur J Cancer, vol.50, issue.1, pp.170-177, 2014.

R. Mody, A. Naranjo, C. Van-ryn, A. L. Yu, W. B. London et al., Irinotecantemozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial, Lancet Oncol, vol.18, issue.7, pp.946-957, 2017.

F. Traore, M. Diawara, E. Pasquier, and N. André, Children Treated With Metronomic Chemotherapy in a Low-income Country: METRO-MALI-01, Pediatr Hematol Oncol, vol.33, issue.1, pp.31-35, 2011.

P. Muthusamy, K. V. Chary, and G. K. Nalini, Metronomic Chemotherapy: Seems Prowess to Battle against Cancer in Current Scenario, J Clin Diagn Res, vol.10, issue.11, pp.9-13, 2016.

N. Andre, S. Cointe, V. Barlogis, L. Arnaud, R. Lacroix et al., Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect, Oncotarget, vol.6, issue.26, pp.23008-23022, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01787272

R. Admiraal, M. Van-der-paardt, J. Kobes, L. C. Kremer, G. Bisogno et al., High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma, Cochrane Database Syst Rev, issue.12, p.6669, 2010.